TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation

Archive ouverte

Vallarelli, Andrelou F. | Rachakonda, P. Sivaramakrishna | André, Jocelyne | Heidenreich, Barbara | Riffaud, Laurent | Bensussan, Armand | Kumar, Rajiv | Dumaz, Nicolas

Edité par CCSD ; Impact journals -

International audience. The mechanism of telomerase re-activation in cancer had remained elusive until the discovery of frequent mutations in the promoter of the TERT gene that encodes the catalytic reverse transcriptase subunit of telomerase. We investigated the regulation of TERT expression in melanoma cell lines and our results show that promoter mutations render TERT expression dependent on MAPK activation due to oncogenic BRAF or NRAS mutations. Mutations in the TERT promoter create binding sites for ETS transcription factors. ETS1, expressed in melanoma cell lines, undergoes activating phosphorylation by ERK at Thr38 residue as a consequence of constitutively activated MAPK pathway. We demonstrate that ETS1 binds on the mutated TERT promoter leading to the re-expression of the gene. The inhibition of ETS1 resulted in reduced TERT expression. We provide evidence that the TERT promoter mutations provide a direct link between TERT expression and MAPK pathway activation due to BRAF or NRAS mutations via the transcription factor ETS1.

Consulter en ligne

Suggestions

Du même auteur

PARKIN Inactivation Links Parkinson's Disease to Melanoma

Archive ouverte | Hu, Hui-Han | CCSD

International audience. Background: Melanoma incidence is higher in patients affected by Parkinson's disease (PD) and vice versa, but the genetic link shared by both diseases is unknown. As PARK2 is both a tumor sup...

Genetic variation at KIT locus may predispose to melanoma

Archive ouverte | Bourillon, Agnes | CCSD

International audience. As loss of KIT frequently occurs in melanoma progression, we hypothesized that KIT is implicated in predisposition to melanoma (MM). Thus, we sequenced the KIT coding region in 112 familial M...

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma

Archive ouverte | Tétu, Pauline | CCSD

International audience. KIT is a bona fide oncogene in a subset of melanoma and, ex vivo, KIT inhibitors are very efficient at killing KIT-mutant melanoma cell lines. However, KIT-mutant melanoma tumors tend to show...

Chargement des enrichissements...